Association of MDM2 SNP309 variation with lung cancer risk: Evidence from 7196 cases and 8456 controls

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Zhuo, Wenlei ^a   Zhang, Liang ^a   Zhu, Bo ^a   Ling, Junjun ^a   Chen, Zhengtang ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AFRICAN; ARTICLE; ASIAN; CANCER RISK; CASE CONTROL STUDY; CAUCASIAN; CONTROLLED STUDY; ETHNIC GROUP; ETHNICITY; GENE FREQUENCY; GENOTYPE; HISTOLOGY; HUMAN; LUNG CANCER; MDM2 GENE; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; TUMOR GENE;

CASE-CONTROL STUDIES; FEMALE; GENETIC HETEROGENEITY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUNG NEOPLASMS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-MDM2;

EID: 84864218735     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041546     Document Type: Article

References (71)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Steliga MA, Dresler CM, (2011) Epidemiology of lung cancer: smoking, secondhand smoke, and genetics. Surg Oncol Clin N Am 20: 605-618.
3. Fucic A, Gamulin M, Ferencic Z, Rokotov DS, Katic J, et al. (2010) Lung cancer and environmental chemical exposure: a review of our current state of knowledge with reference to the role of hormones and hormone receptors as an increased risk factor for developing lung cancer in man. Toxicol Pathol 38: 849-855.
4. Yokota J, Shiraishi K, Kohno T, (2010) Genetic basis for susceptibility to lung cancer: Recent progress and future directions. Adv Cancer Res 109: 51-72.
5. Wang JJ, Zheng Y, Sun L, Wang L, Yu PB, et al. (2011) CYP1A1 Ile462Val polymorphism and susceptibility to lung cancer: a meta-analysis based on 32 studies. Eur J Cancer Prev 20: 445-452.
6. Carlsten C, Sagoo GS, Frodsham AJ, Burke W, Higgins JP, (2008) Glutathione S-transferase M1 (GSTM1) polymorphisms and lung cancer: a literature-based systematic HuGE review and meta-analysis. Am J Epidemiol 167: 759-774.
7. Chen B, Qiu LX, Li Y, Xu W, Wang XL, et al. (2010) The CYP1B1 Leu432Val polymorphism contributes to lung cancer risk: evidence from 6501 subjects. Lung Cancer 70: 247-252.
8. Li Y, Qiu LX, Shen XK, Lv XJ, Qian XP, et al. (2009) A meta-analysis of TP53 codon 72 polymorphism and lung cancer risk: evidence from 15,857 subjects. Lung Cancer 66: 15-21.
9. Cui D, Wang Z, Zhao E, Ma J, Lu W, (2011) NAT2 polymorphism and lung cancer risk: a meta-analysis. Lung Cancer 73: 153-157.
10. Cao C, Zhang YM, Wang R, Sun SF, Chen ZB, et al. (2011) Excision repair cross complementation group 1 polymorphisms and lung cancer risk: a meta-analysis. Chin Med J (Engl) 124: 2203-2208.
11. Wang J, Cao C, Luo H, Xiong S, Xu Y, et al. (2011) Tumour necrosis factor alpha-308G/A polymorphism and risk of the four most frequent cancers: a meta-analysis. Int J Immunogenet 38: 311-320.
12. Wu H, Leng RP, (2011) UBE4B, a ubiquitin chain assembly factor, is required for MDM2-mediated p53 polyubiquitination and degradation. Cell Cycle 10: 1912-1915.
13. Poyurovsky MV, Katz C, Laptenko O, Beckerman R, Lokshin M, et al. (2010) The C terminus of p53 binds the N-terminal domain of MDM2. Nat Struct Mol Biol 17: 982-989.
14. Toledo F, Wahl GM, (2007) MDM2 and MDM4: p53 regulators as targets in anticancer therapy. Int J Biochem Cell Biol 39: 1476-1482.
15. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, et al. (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119: 591-602.
16. Bai J, Dai J, Yu H, Shen H, Chen F, (2009) Cigarette smoking, MDM2 SNP309, gene-environment interactions, and lung cancer risk: a meta-analysis. J Toxicol Environ Health A 72: 677-682.
17. Gui XH, Qiu LX, Zhang HF, Zhang DP, Zhong WZ, et al. (2009) MDM2 309 T/G polymorphism is associated with lung cancer risk among Asians. Eur J Cancer 45: 2023-2026.
18. Higgins JP, Thompson SG, Deeks JJ, Altman DG, (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557-560.
19. Mantel N, Haenszel W, (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22: 719-748.
20. DerSimonian R, Laird N, (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188.
21. Munafo MR, Clark TG, Flint J, (2004) Assessing publication bias in genetic association studies: evidence from a recent meta-analysis. Psychiatry Res 129: 39-44.
22. Egger M, Davey Smith G, Schneider M, Minder C, (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634.
23. Jun HJ, Park SH, Lee WK, Choi JE, Jang JS, et al. (2007) Combined effects of p73 and MDM2 polymorphisms on the risk of lung cancer. Mol Carcinog 46: 100-105.
24. Park SH, Choi JE, Kim EJ, Jang JS, Han HS, et al. (2006) MDM2 309T&G polymorphism and risk of lung cancer in a Korean population. Lung Cancer 54: 19-24.
25. Chien WP, Wong RH, Cheng YW, Chen CY, Lee H, (2010) Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors. Ann Surg Oncol 17: 1194-1202.
26. Dong J, Ren B, Hu Z, Chen J, Hu L, et al. (2011) MDM2 SNP309 contributes to non-small cell lung cancer survival in Chinese. Mol Carcinog 50: 433-438.
27. Han JY, Lee GK, Jang DH, Lee SY, Lee JS, (2008) Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer. Cancer 113: 799-807.
28. Heist RS, Zhou W, Chirieac LR, Cogan-Drew T, Liu G, et al. (2007) MDM2 polymorphism, survival, and histology in early-stage non-small-cell lung cancer. J Clin Oncol 25: 2243-2247.
29. Liu L, Wu C, Wang Y, Zhong R, Duan S, et al. (2011) Combined effect of genetic polymorphisms in P53, P73, and MDM2 on non-small cell lung cancer survival. J Thorac Oncol 6: 1793-1800.
30. Chua HW, Ng D, Choo S, Lum SS, Li H, et al. (2010) Effect of MDM2 SNP309 and p53 codon 72 polymorphisms on lung cancer risk and survival among non-smoking Chinese women in Singapore. BMC Cancer 10: 88.
31. Hu Z, Ma H, Lu D, Qian J, Zhou J, et al. (2006) Genetic variants in the MDM2 promoter and lung cancer risk in a Chinese population. Int J Cancer 118: 1275-1278.
32. Kohno T, Kunitoh H, Mimaki S, Shiraishi K, Kuchiba A, et al. (2011) Contribution of the TP53, OGG1, CHRNA3, and HLA-DQA1 genes to the risk for lung squamous cell carcinoma. J Thorac Oncol 6: 813-817.
33. Li G, Zhai X, Zhang Z, Chamberlain RM, Spitz MR, et al. (2006) MDM2 gene promoter polymorphisms and risk of lung cancer: a case-control analysis. Carcinogenesis 27: 2028-2033.
34. Lind H, Zienolddiny S, Ekstrom PO, Skaug V, Haugen A, (2006) Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer. Int J Cancer 119: 718-721.
35. Liu G, Wheatley-Price P, Zhou W, Park S, Heist RS, et al. (2008) Genetic polymorphisms of MDM2, cumulative cigarette smoking and nonsmall cell lung cancer risk. Int J Cancer 122: 915-918.
36. Mittelstrass K, Sauter W, Rosenberger A, Illig T, Timofeeva M, et al. (2008) Early onset lung cancer, cigarette smoking and the SNP309 of the murine double minute-2 (MDM2) gene. BMC Cancer 8: 113.
37. Pine SR, Mechanic LE, Bowman ED, Welsh JA, Chanock SC, et al. (2006) MDM2 SNP309 and SNP354 are not associated with lung cancer risk. Cancer Epidemiol Biomarkers Prev 15: 1559-1561.
38. Zhang X, Miao X, Guo Y, Tan W, Zhou Y, et al. (2006) Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Hum Mutat 27: 110-117.
39. Tobias A, (1999) Assessing the influence of a single study in the meta-analysis estimate. Stata Techn Bull 8: 15-17.
40. Landi MT, Chatterjee N, Yu K, Goldin LR, Goldstein AM, et al. (2009) A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. Am J Hum Genet 85: 679-691.
41. Hung RJ, McKay JD, Gaborieau V, Boffetta P, Hashibe M, et al. (2008) A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 452: 633-637.
42. Wang Y, Broderick P, Webb E, Wu X, Vijayakrishnan J, et al. (2008) Common 5p15.33 and 6p21.33 variants influence lung cancer risk. Nat Genet 40: 1407-1409.
43. Shi J, Chatterjee N, Rotunno M, Wang Y, Pesatori AC, et al. (2012) Inherited Variation at Chromosome 12p13.33, Including RAD52, Influences the Risk of Squamous Cell Lung Carcinoma. Cancer Discov 2: 131-139.
44. Ahn MJ, Won HH, Lee J, Lee ST, Sun JM, et al. (2012) The 18p11.22 locus is associated with never smoker non-small cell lung cancer susceptibility in Korean populations. Hum Genet 131: 365-372.
45. Hu Z, Wu C, Shi Y, Guo H, Zhao X, et al. (2011) A genome-wide association study identifies two new lung cancer susceptibility loci at 13q12.12 and 22q12.2 in Han Chinese. Nat Genet 43: 792-796.
46. Hosgood HD, 3rd, Wang WC, Hong YC, Wang JC, Chen K, et al (2012) Genetic variant in TP63 on locus 3q28 is associated with risk of lung adenocarcinoma among never-smoking females in Asia. Hum Genet.
47. Cai X, Yang M, (2011) The functional MDM2 T309G genetic variant but not P53 Arg72Pro polymorphism is associated with risk of sarcomas: a meta-analysis. J Cancer Res Clin Oncol.
48. Li Y, Zhao H, Sun L, Huang L, Yang Q, et al. (2011) MDM2 SNP309 is associated with endometrial cancer susceptibility: a meta-analysis. Hum Cell 24: 57-64.
49. Liu GY, Jiang DK, Shen SQ, Yu L, (2011) MDM2 SNP309T&G polymorphism with hepatocellular carcinoma risk: a meta-analysis. Arch Med Res 42: 149-155.
50. Economopoulos KP, Sergentanis TN, (2010) Differential effects of MDM2 SNP309 polymorphism on breast cancer risk along with race: a meta-analysis. Breast Cancer Res Treat 120: 211-216.
51. Liu J, Zheng Y, Lei D, Liu D, Xu F, et al. (2011) MDM2 309T&G Polymorphism and Risk of Squamous Cell Carcinomas of Head and Neck: a Meta-analysis. Asian Pac J Cancer Prev 12: 1899-1903.
52. Manfredi JJ, (2010) The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor. Genes Dev 24: 1580-1589.
53. Hamard PJ, Manfredi JJ, (2012) Mdm2's dilemma: to degrade or to translate p53? Cancer Cell 21: 3-5.
54. Pfeifer GP, Denissenko MF, Olivier M, Tretyakova N, Hecht SS, et al. (2002) Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene 21: 7435-7451.
55. Gajjar M, Candeias MM, Malbert-Colas L, Mazars A, Fujita J, et al. (2012) The p53 mRNA-Mdm2 interaction controls Mdm2 nuclear trafficking and is required for p53 activation following DNA damage. Cancer Cell 21: 25-35.
56. Roos WP, Kaina B, (2006) DNA damage-induced cell death by apoptosis. Trends Mol Med 12: 440-450.
57. Broet P, Dalmasso C, Tan EH, Alifano M, Zhang S, et al. (2011) Genomic profiles specific to patient ethnicity in lung adenocarcinoma. Clin Cancer Res 17: 3542-3550.
58. Charloux A, Rossignol M, Purohit A, Small D, Wolkove N, et al. (1997) International differences in epidemiology of lung adenocarcinoma. Lung Cancer 16: 133-143.
59. Bogush TA, Dudko EA, Beme AA, Bogush EA, Kim AI, et al. (2010) Estrogen receptors, antiestrogens, and non-small cell lung cancer. Biochemistry (Mosc) 75: 1421-1427.
60. Verma MK, Miki Y, Sasano H, (2011) Sex steroid receptors in human lung diseases. J Steroid Biochem Mol Biol 127: 216-222.
61. Brekman A, Singh KE, Polotskaia A, Kundu N, Bargonetti J, (2011) A p53-independent role of Mdm2 in estrogen-mediated activation of breast cancer cell proliferation. Breast Cancer Res 13: R3.
62. Gu L, Findley HW, Zhou M, (2002) MDM2 induces NF-kappaB/p65 expression transcriptionally through Sp1-binding sites: a novel, p53-independent role of MDM2 in doxorubicin resistance in acute lymphoblastic leukemia. Blood 99: 3367-3375.
63. Hu W, Feng Z, Ma L, Wagner J, Rice JJ, et al. (2007) A single nucleotide polymorphism in the MDM2 gene disrupts the oscillation of p53 and MDM2 levels in cells. Cancer Res 67: 2757-2765.
64. Petz LN, Ziegler YS, Schultz JR, Kim H, Kemper JK, et al. (2004) Differential regulation of the human progesterone receptor gene through an estrogen response element half site and Sp1 sites. J Steroid Biochem Mol Biol 88: 113-122.
65. Bond GL, Hirshfield KM, Kirchhoff T, Alexe G, Bond EE, et al. (2006) MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res 66: 5104-5110.
66. Pauk N, Kubik A, Zatloukal P, Krepela E, (2005) Lung cancer in women. Lung Cancer 48: 1-9.
67. Ben-Zaken Cohen S, Pare PD, Man SF, Sin DD, (2007) The growing burden of chronic obstructive pulmonary disease and lung cancer in women: examining sex differences in cigarette smoke metabolism. Am J Respir Crit Care Med 176: 113-120.
68. Sato S, Nakamura Y, Tsuchiya E, (1994) Difference of allelotype between squamous cell carcinoma and adenocarcinoma of the lung. Cancer Res 54: 5652-5655.
69. Chaar I, Arfaoui TA, El Amine el HO, Mahmoud LB, Khiari M, et al. (2012) Impact of MDM2 polymorphism: increased risk of developing colorectal cancer and a poor prognosis in the Tunisian population. Eur J Gastroenterol Hepatol 24: 320-327.
70. Dong HJ, Fang C, Fan L, Zhu DX, Wang DM, et al. (2012) MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL. Int J Cancer 130: 2054-2061.
71. Jaboin JJ, Hwang M, Perez CA, Cooper C, Chen H, et al. (2011) No evidence for association of the MDM2-309 T/G promoter polymorphism with prostate cancer outcomes. Urol Oncol 29: 319-323.